查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1932157

分子影像CRO市场依显像模式、应用、服务类型和最终用户划分，全球预测（2026-2032年）

Molecular Imaging CRO Market by Imaging Modality, Application, Service Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，分子影像 CRO 市场价值将达到 32.4 亿美元，到 2026 年将成长至 37 亿美元，到 2032 年将达到 98.4 亿美元，复合年增长率为 17.17%。

关键市场统计数据
基准年 2025 32.4亿美元
预计年份：2026年 37亿美元
预测年份 2032 98.4亿美元
复合年增长率 (%) 17.17%

现代化的分子影像CRO能力、技术整合和营运需求介绍，旨在重塑临床前和临床影像工作流程。

分子影像技术融合了生物学、化学和临床应用，能够从分子和细胞层面精细地可视化疾病。近年来，硬体、探针化学和计算分析技术的进步拓展了影像技术在治疗研发、转化研究和临床决策支援中的应用。因此，从学术研究机构到製药公司，各方相关人员越来越依赖专业的受託研究机构来提供可重复、合规且高度精确的影像资料。

技术成熟度、放射性示踪剂创新和数据驱动分析的融合，正在重新定义生命科学领域的分子影像研究和服务提供。

分子影像领域经历了一系列变革，这些变革的驱动力包括技术成熟、监管要求不断演变以及计算方法的融合。硬体创新提高了磁振造影（MRI）、正子断层扫描（PET）、单光子发射电脑断层扫描（SPECT）和光学平台的空间和时间分辨率，使研究人员能够在临床前和临床环境中提出更详细的生物学问题。同时，放射性追踪剂的化学性质也变得更加灵活，拓展了可成像标靶的多样性，并加速了从药物发现到首次人体试验的转化。

评估关税变化对分子影像CRO营运的营运和供应链影响，以及维持研究连续性和资料完整性的策略

包括关税调整和贸易措施在内的政策环境正在影响整个分子影像生态系统的营运规划。关税正在衝击特种耗材、仪器零件和进口放射化学前驱物的供应链，迫使许多机构重新评估供应商多元化、库存策略和采购区域。这些变化可能会延长关键试剂和组件的前置作业时间，因此制定紧急时应对计画和加强与供应商的关係对于维持研究进度至关重要。

关键的细分洞察揭示了分子影像方式的选择、临床应用、服务模式和最终用户需求如何共同影响专案设计和供应商选择。

细分有助于系统地了解不同模式、应用程式、服务类型和最终用户的需求驱动因素、能力和服务匹配。从成像模式的角度来看，磁振造影 (MRI) 对于高解析度的解剖和功能终点评估至关重要，而光学成像（包括生物发光和萤光技术）则可提供快速且经济高效的临床前筛检和机制阐明。正子断层扫描 (PET) 和单光子发射电脑断层扫描 (SPECT) 及其各自的临床和临床前亚类，有助于标靶结合评估和剂量测定，提供弥合转化医学差距的定量分子数据。

区域趋势和基础设施差异将决定成像能力、法规结构和协作网路将如何影响全球市场的专案执行。

区域趋势影响着分子影像价值链中的技术能力、法规环境和合作模式。在美洲，强大的产学研合作和成熟的临床试验基础设施支持着影像生物标记的快速转化研究，而专业服务供应商提供与药物研发需求相契合的广泛的临床前和临床影像服务。这个生态系统正在推动PET和SPECT应用以及先进MRI通讯协定的创新。

策略性企业行动与能力差异化因素：定义分子影像合约研究市场的竞争格局、伙伴关係模式与价值提案

分子影像CRO领域的竞争者透过专注于专业技术、整合服务组合或地理覆盖范围来展现差异化策略。一些供应商强调端到端能力，将放射性示踪剂开发、影像撷取和进阶数据分析相结合，以最大限度地减少转化阻力并提供承包工程。另一些供应商则专注于特定优势领域，例如高通量光学成像平台或临床PET/SPECT服务，并在特定领域凭藉速度和技术卓越性建立声誉。

给领导者的具体建议：增强韧性，规范分析流程，并发展能够加速转化研究并满足专案进度要求的综合服务模式。

产业领导者应制定行动计划，以增强韧性、加速转换价值并提升竞争优势。首先，应优先建构模组化服务架构，整合放射性示踪剂开发、影像撷取和数据分析，同时让客户建构客製化的研究方案。这种方法可以减轻申办者的负担，并支持在各种研究设计中获得可重复的结果。其次，应深化与供应商的关係，并对关键耗材和合成前驱物的替代来源进行评估，以降低供应链中断和关税带来的风险。

结合专家访谈、能力初步分析和文献综述的稳健混合研究途径，确保了研究结果的可操作性和可重复性。

本研究采用多维度方法，结合专家访谈、一手资料收集以及对技术、监管和营运文献的系统性回顾。对影像科学家、放射化学家、临床研究人员和服务营运经理的访谈，提供了关于成像方式选择、示踪剂开发路径以及不断变化的终端用户期望的定性见解。一手资料收集着重于不同类型服务供应商的服务产品、平台功能和伙伴关係模式，旨在了解各公司如何满足特定影像方式和应用主导的需求。

本文全面探讨如何策略性地整合影像技术专长、示踪剂化学和分析技术，以促进转化研究的成功和诊断影像专案的韧性。

总之，分子影像领域正朝着以品质主导的综合服务方向发展，将影像技术专长、示踪剂创新和分析技术融合在一起，以支持转化医学目标的实现。能够将放射性示踪剂开发、影像服务和先进数据分析相结合，同时保持健全品质系统的供应商，将更有能力满足学术机构、受託研究机构、医院和诊断中心以及製药和生物技术赞助商的需求。随着成像方式的不断多样化（例如，磁振造影、各种光学成像、临床和临床前正子断层扫描、临床和临床前单光子发射电脑断层扫描），成功的专案将取决于对成像方式的谨慎选择和协调一致的分析流程。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依成像方式分類的分子影像CRO市场

  • MRI
  • 光学成像
    • 生物发光成像
    • 萤光影像
  • PET
    • 临床PET
    • 临床前PET
  • SPECT
    • 临床SPECT
    • 临床前SPECT

第九章 按应用分類的分子影像CRO市场

  • 心臟病学
    • 心臟衰竭影像学
    • 心肌灌注显像
  • 发炎
    • 自体免疫疾病影像学
    • 感染疾病影像学
  • 神经病学
    • 阿兹海默症影像学
    • 帕金森氏症影像学
  • 肿瘤学
    • 血液肿瘤影像学
    • 固态肿瘤影像

第十章 分子影像CRO市场依服务类型划分

  • 数据分析
  • 影像服务
  • 放射性示踪剂的研发

第十一章 分子影像CRO市场（依最终用户划分）

  • 学术研究机构
  • 合约研究机构
  • 医院和诊断中心
  • 製药和生物技术公司

第十二章 分子影像CRO市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 分子影像CRO市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国分子影像CRO市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 美国分子影像CRO市场

第十六章：中国分子影像CRO市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ABX-CRO Advanced Pharmaceutical Services, LLC
  • Bioclinica, Inc.
  • Biomedical Systems Corporation
  • Biospective, Inc.
  • Biotrial, SA
  • Blue Earth Diagnostics Ltd.
  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • Gubra A/S
  • ICON plc
  • Image Analysis Group, LLC
  • Imaging Endpoints, Inc.
  • IQVIA Holdings Inc.
  • Labcorp Drug Development, Inc.
  • Medpace Holdings, Inc.
  • Micron, Inc.
  • Oncodesign SA
  • Parexel International Corporation
  • Serac Life Sciences, Inc.
  • Tracer CRO, LLC
Product Code: MRR-7B550E008FB7

The Molecular Imaging CRO Market was valued at USD 3.24 billion in 2025 and is projected to grow to USD 3.70 billion in 2026, with a CAGR of 17.17%, reaching USD 9.84 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.24 billion
Estimated Year [2026] USD 3.70 billion
Forecast Year [2032] USD 9.84 billion
CAGR (%) 17.17%

A contemporary introduction to molecular imaging CRO capabilities, technological convergence, and the operational demands reshaping preclinical and clinical imaging workflows

Molecular imaging sits at the intersection of biology, chemistry, and clinical translation, enabling nuanced visualization of disease at molecular and cellular levels. Recent advances in hardware, probe chemistry, and computational analytics have expanded the applicability of imaging across therapeutic development, translational research, and clinical decision support. As a result, stakeholders from academic research institutes to pharmaceutical developers increasingly rely on specialized contract research organizations to deliver reproducible, compliant, and high-fidelity imaging data.

Within this environment, modalities such as MRI, Optical Imaging, PET, and SPECT play complementary roles. MRI provides rich anatomical and functional context, Optical Imaging - including bioluminescence and fluorescence techniques - accelerates preclinical screening and mechanistic studies, and PET and SPECT span preclinical and clinical workflows for quantitative molecular readouts. Consequently, organizations must align modality selection with study objectives, regulatory expectations, and downstream analytical requirements.

Given the complexity of modern imaging programs, service offerings now emphasize integrated solutions that include imaging services, radiotracer development, and advanced data analysis. These combined capabilities reduce time-to-insight and mitigate translational gaps. Looking forward, the field is positioned for continued convergence of imaging modalities with AI-driven analytics and purpose-built radiochemistry, shaping the way therapeutic candidates and diagnostics are evaluated across cardiology, neurology, inflammation, and oncology applications

How technological maturation, radiotracer innovation, and data-driven analytics are converging to redefine molecular imaging research and service delivery in life sciences

The landscape of molecular imaging has undergone a series of transformative shifts driven by technological maturation, evolving regulatory expectations, and the integration of computational methods. Hardware innovation has improved spatial and temporal resolution across MRI, PET, SPECT, and optical platforms, enabling investigators to ask more granular biological questions across both preclinical and clinical settings. At the same time, radiotracer chemistry has become more agile, expanding the diversity of targets that can be imaged and accelerating transitions from discovery to first-in-human evaluation.

Parallel to hardware and chemistry advances, data analytics has emerged as a core competency. Sophisticated image processing, quantitative modeling, and machine learning approaches now uncover subtle signal patterns and support biomarker qualification. This analytical evolution elevates the role of data analysis services, which complement imaging services and radiotracer development to offer end-to-end solutions. Moreover, these changes are influencing how end users-academic research institutes, contract research organizations, hospitals and diagnostic centers, and pharmaceutical biotech-structure collaborations, outsource capabilities, and define success metrics.

Additionally, cross-modality strategies are more common, with hybrid study designs leveraging the anatomical context of MRI, the sensitivity of PET and SPECT in both clinical and preclinical formats, and the rapid throughput of bioluminescence and fluorescence optical imaging. These convergent strategies, combined with stricter reproducibility standards and demand for regulatory-grade data, are compelling providers to adopt standardized pipelines, robust quality systems, and transparent reporting frameworks that support multi-stakeholder decision-making

Assessing the operational and supply chain ramifications of tariff changes on molecular imaging CRO operations and strategies to preserve study continuity and data integrity

The policy environment, including tariff adjustments and trade measures, influences operational planning across the molecular imaging ecosystem. Tariffs affect supply chains for specialized consumables, instrumentation components, and imported radiochemistry precursors, leading many organizations to reassess supplier diversification, inventory strategies, and sourcing geographies. In turn, these shifts can extend lead times for critical reagents and parts, necessitating contingency planning and stronger vendor relationships to sustain study timelines.

As a consequence, service providers have revised procurement practices and prioritized local supplier development where feasible. This transition often involves qualifying alternate vendors, increasing stock levels for key items, and collaborating closely with equipment manufacturers to secure maintenance and spare parts. For radiotracer development, changes in precursor availability have prompted laboratories to explore alternative synthetic routes and to invest in modular synthesis platforms that offer greater flexibility under constrained supply conditions.

Moreover, tariff-driven cost pressures are encouraging providers and end users to examine the full cost structure of imaging programs, identifying opportunities to increase operational efficiency without compromising data quality. Increased attention to platform standardization, assay harmonization, and remote data processing helps offset some of these pressures. Ultimately, a strategic response to tariff impacts emphasizes resilience through diversified sourcing, flexible workflows, and strengthened supplier partnerships to protect study continuity and scientific integrity

Key segmentation insights that reveal how modality choices, clinical applications, service types, and end-user needs collectively shape program design and vendor selection in molecular imaging

Segmentation provides a structured way to understand demand drivers, capabilities, and service alignment across modalities, applications, service types, and end users. When analyzed through the lens of imaging modality, MRI remains essential for high-resolution anatomical and functional endpoints, while optical imaging-comprising bioluminescence and fluorescence techniques-delivers rapid, cost-effective preclinical screening and mechanistic insights. PET and SPECT, each with clinical and preclinical subdivisions, serve as quantitative molecular readouts that bridge translational gaps and support target engagement and dosimetry assessments.

Looking at application domains, cardiology studies focused on heart failure imaging and myocardial perfusion imaging require distinct protocols, tracer selection, and analytical pipelines compared with inflammation workstreams addressing autoimmune imaging and infection imaging. Neurology programs centered on Alzheimer's imaging and Parkinson's imaging demand rigorous longitudinal designs, sensitive radiotracers, and harmonized imaging endpoints. Oncology efforts span hematological tumor imaging and solid tumor imaging, each presenting unique biodistribution, microenvironmental, and tracer uptake considerations that shape study design and interpretation.

Service type segmentation highlights the interdependence of imaging services, radiotracer development, and data analysis. Integrated offerings that combine high-quality imaging acquisition with bespoke tracer chemistry and robust quantitative analytics enable more reliable biomarker readouts. Finally, end-user segmentation-encompassing academic research institutes, contract research organizations, hospitals and diagnostic centers, and pharmaceutical biotech-illuminates purchasing behavior, regulatory expectations, and preferred engagement models, informing how providers position their capabilities and structure collaborations

Regional dynamics and infrastructure differences that determine how imaging capabilities, regulatory frameworks, and collaborative networks influence program execution across global markets

Regional dynamics influence capabilities, regulatory contexts, and collaboration models across the molecular imaging value chain. In the Americas, robust academic-industrial partnerships and a mature clinical trial infrastructure support rapid translation of imaging biomarkers, while specialist service providers deliver a wide range of preclinical and clinical imaging services that align with pharmaceutical development needs. This ecosystem fosters innovation in PET and SPECT applications as well as advanced MRI protocols.

In Europe, the Middle East & Africa, regulatory harmonization efforts and strong research networks underpin collaborative multicenter studies, and hospitals and diagnostic centers often serve as hubs for early clinical imaging programs. Academic research institutes contribute foundational science, and contract research organizations operate as integrators of modality-specific expertise and centralized analytics. Across this combined region, radiotracer development benefits from dense networks of radiochemistry facilities and cross-border collaborations.

The Asia-Pacific region continues to expand its capacity across imaging modalities and service types, driven by increased investment in healthcare infrastructure and growing pharmaceutical and biotech activity. Local manufacturers, growing numbers of academic research institutes, and an expanding community of clinical imaging centers are enabling more regionalized study execution. Together, these regional distinctions highlight how geography informs supply chain decisions, regulatory engagement, and partner selection for imaging programs

Strategic company behaviors and capability differentiators that define competition, partnership models, and value propositions within the molecular imaging contract research market

Companies competing in the molecular imaging CRO space demonstrate differentiated strategies by concentrating on specialized modality expertise, integrated service portfolios, or geographic coverage. Some providers emphasize end-to-end capabilities, combining radiotracer development, imaging acquisition, and advanced data analysis to minimize translational friction and deliver turnkey programs. Others focus on niche strengths such as high-throughput optical imaging platforms or clinical PET/SPECT services, building reputations for speed and technical excellence in targeted segments.

Strategic partnerships and alliances are common, enabling firms to extend their service reach without diluting core competencies. Collaboration between radiochemistry specialists and imaging centers, for example, facilitates access to novel tracers while maintaining compliance with clinical manufacturing standards. At the same time, investment in digital infrastructure and analytics capabilities distinguishes companies that can provide standardized, regulatory-grade outputs and support multi-site harmonization.

Operationally, leading organizations place emphasis on quality management systems, reproducible protocols, and transparent reporting to meet the expectations of pharmaceutical biotech sponsors and academic consortia. This focus on reliability, combined with flexible engagement models, positions select providers as preferred partners for complex translational projects and late-stage development programs

Actionable recommendations for leaders to build resilience, standardize analytics, and craft integrated service models that accelerate translation and protect program timelines

Industry leaders should pursue an action agenda that strengthens resilience, accelerates translational value, and enhances competitive differentiation. First, prioritize modular service architectures that integrate radiotracer development, imaging acquisition, and data analysis while allowing clients to assemble tailored study packages. This approach reduces friction for sponsors and supports reproducible outcomes across varied study designs. Second, deepen supplier relationships and qualify alternate sources for critical consumables and synthesis precursors to mitigate supply chain disruptions and tariff-driven risks.

Third, invest in analytics platforms and standardized processing pipelines that support cross-site harmonization and regulatory readiness. Demonstrating consistent, validated quantitative outputs will increasingly become a discriminator in partner selection. Fourth, expand collaborative networks with academic research institutes and hospital centers to accelerate access to patient populations, novel biomarkers, and platform validation opportunities. Finally, adopt flexible commercial models that align with client needs, including modular pricing, data access options, and advisory services to support study design and regulatory engagement. Collectively, these actions position organizations to deliver higher-value programs, preserve study continuity under changing trade conditions, and capture demand across diverse application areas

A robust mixed-methods research approach combining expert interviews, primary capability mapping, and literature synthesis to ensure actionable and reproducible insights

This research draws upon a multidimensional methodology that combines expert interviews, primary data collection, and a structured review of technological, regulatory, and operational literature. Interviews with imaging scientists, radiochemists, clinical investigators, and service operations leaders provided qualitative perspectives on modality selection, tracer development pathways, and the evolving expectations of end users. Primary data collection focused on service offerings, platform capabilities, and partnership models across provider types to map how firms address modality-specific and application-driven requirements.

Complementing qualitative inputs, the approach included systematic review of recent peer-reviewed studies, technical white papers, and publicly available regulatory guidance to ensure that interpretations reflect contemporary standards for image acquisition, quantitation, and clinical validation. Emphasis was placed on reproducibility, methodological transparency, and harmonization practices in multi-site studies. Triangulation of sources ensured that conclusions were grounded in convergent evidence and practical experience, while iterative validation with industry practitioners refined the framing of service models and recommended operational strategies

Concluding perspective on the strategic integration of modality expertise, tracer chemistry, and analytics to drive translational success and program resilience in imaging

In summary, the molecular imaging landscape is evolving toward integrated, quality-driven service delivery where modality expertise, tracer innovation, and analytics converge to support translational objectives. Providers that combine radiotracer development, imaging services, and advanced data analysis while maintaining robust quality systems will be best positioned to meet the needs of academic research institutes, contract research organizations, hospitals and diagnostic centers, and pharmaceutical biotech sponsors. As modalities continue to diversify-spanning MRI, optical imaging variants, clinical and preclinical PET, and clinical and preclinical SPECT-successful programs will rely on deliberate modality selection and harmonized analytical pipelines.

Regional differences underscore the importance of local partnerships and supply chain strategies, and policy changes affecting tariffs reinforce the need for procurement resilience and operational flexibility. Ultimately, organizations that adopt modular service models, invest in validated analytics, and cultivate strategic collaborations will accelerate translational impact and protect study timelines amid changing market conditions. Continued emphasis on reproducibility, regulatory alignment, and transparent reporting will further elevate the role of specialized imaging CROs in supporting therapeutic and diagnostic innovation

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Molecular Imaging CRO Market, by Imaging Modality

  • 8.1. MRI
  • 8.2. Optical Imaging
    • 8.2.1. Bioluminescence Imaging
    • 8.2.2. Fluorescence Imaging
  • 8.3. PET
    • 8.3.1. Clinical PET
    • 8.3.2. Preclinical PET
  • 8.4. SPECT
    • 8.4.1. Clinical SPECT
    • 8.4.2. Preclinical SPECT

9. Molecular Imaging CRO Market, by Application

  • 9.1. Cardiology
    • 9.1.1. Heart Failure Imaging
    • 9.1.2. Myocardial Perfusion Imaging
  • 9.2. Inflammation
    • 9.2.1. Autoimmune Imaging
    • 9.2.2. Infection Imaging
  • 9.3. Neurology
    • 9.3.1. Alzheimer's Imaging
    • 9.3.2. Parkinson's Imaging
  • 9.4. Oncology
    • 9.4.1. Hematological Tumor Imaging
    • 9.4.2. Solid Tumor Imaging

10. Molecular Imaging CRO Market, by Service Type

  • 10.1. Data Analysis
  • 10.2. Imaging Services
  • 10.3. Radiotracer Development

11. Molecular Imaging CRO Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Diagnostic Centers
  • 11.4. Pharmaceutical Biotech

12. Molecular Imaging CRO Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Molecular Imaging CRO Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Molecular Imaging CRO Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Molecular Imaging CRO Market

16. China Molecular Imaging CRO Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. ABX-CRO Advanced Pharmaceutical Services, LLC
  • 17.6. Bioclinica, Inc.
  • 17.7. Biomedical Systems Corporation
  • 17.8. Biospective, Inc.
  • 17.9. Biotrial, SA
  • 17.10. Blue Earth Diagnostics Ltd.
  • 17.11. Charles River Laboratories International, Inc.
  • 17.12. Crown Bioscience, Inc.
  • 17.13. Gubra A/S
  • 17.14. ICON plc
  • 17.15. Image Analysis Group, LLC
  • 17.16. Imaging Endpoints, Inc.
  • 17.17. IQVIA Holdings Inc.
  • 17.18. Labcorp Drug Development, Inc.
  • 17.19. Medpace Holdings, Inc.
  • 17.20. Micron, Inc.
  • 17.21. Oncodesign SA
  • 17.22. Parexel International Corporation
  • 17.23. Serac Life Sciences, Inc.
  • 17.24. Tracer CRO, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MOLECULAR IMAGING CRO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MOLECULAR IMAGING CRO MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MOLECULAR IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY FLUORESCENCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY FLUORESCENCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY FLUORESCENCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CLINICAL PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CLINICAL PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CLINICAL PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PRECLINICAL PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PRECLINICAL PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PRECLINICAL PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CLINICAL SPECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CLINICAL SPECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CLINICAL SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PRECLINICAL SPECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PRECLINICAL SPECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PRECLINICAL SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HEART FAILURE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HEART FAILURE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HEART FAILURE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY MYOCARDIAL PERFUSION IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY MYOCARDIAL PERFUSION IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY MYOCARDIAL PERFUSION IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY AUTOIMMUNE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY AUTOIMMUNE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY AUTOIMMUNE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY INFECTION IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY INFECTION IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY INFECTION IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ALZHEIMER'S IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ALZHEIMER'S IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ALZHEIMER'S IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PARKINSON'S IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PARKINSON'S IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PARKINSON'S IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HEMATOLOGICAL TUMOR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HEMATOLOGICAL TUMOR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HEMATOLOGICAL TUMOR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SOLID TUMOR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SOLID TUMOR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SOLID TUMOR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY RADIOTRACER DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY RADIOTRACER DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY RADIOTRACER DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 213. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 214. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 215. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 218. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 248. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 249. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 250. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 251. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 254. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. G7 MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 261. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 262. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 263. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 266. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. NATO MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL MOLECULAR IMAGING CRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA MOLECULAR IMAGING CRO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY INFLAMMATION, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA MOLECULAR IMAGING CRO MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)